LATENT HEPATIC ENCEPHALOPATHY IN PATIENTS WITH MINIMUM HEPATIC FIBROSIS

Study objective. To evaluate effect of peroral administration of L-ornitin-L-aspartate (LOLA) on the frequency of road traffic accidents in persons with hepatic disease at the pre-cirrhotic stage. Material and methods. The study included 42 patients – men aged 25-45, drivers with the driving experience no less than 3 years acknowledged guilty of 3-4 road traffic accidents in the recent 3 years. All patients were diagnosed with chronic hepatitis C (genotype 1), with minimum or low activity of aminotransferase and the minimum hepatic fibrosis. Diseases that could affect performance of the road traffic accident as well as external factors (state of the car, road surfacing, weather conditions). LOLA therapy at a dosage 9 g per day was done by 2-month cycles with 2-month intervals, by the present moment the total duration reached 5 months. Each month biochemical blood analysis, blood ammonium ion concentration determination and psychometric tests were performed. Results. Ammonium ion concentration was reduced in a month after start of LOLA (from 145.4 μmol/l to 130.3 μmol/l, р = 0,016) maintaining stable tendency to reduction during the therapy until achievement of the medium level 90.4 μmol/l (р = 0.003) by the 6th month. Results of the flicker fusion frequency test significantly improved by the end of the first course LOLA (р = 0,003), remaining at the achieved level during the therapy. The results of the number connection test significantly improved by the end of the first month of therapy (р < 0.001), with maintenance of the trend on the background of the ubsequent courses. In the specified period of observation no road traffic accidents through the fault of persons included in the study, according to the data of the STSI. Conclusions. The intermitting LOLA therapy in patients with chronic hepatitis C and the minimum fibrosis reconditions quick reduction of the ammonium ion concentration in the blood and significant improvement of psychometric tests values.

1. Ennaifer R, Cheikh M, Hefaiedh R et al. Minimal hepatic encephalopathy: a better diagnostic to improve prognostic. Presse Med, 2014, 43: 127-133.

2. Tiberi O, Tognarelli JM, Cook NA et al. Diagnosing and treating hepatic encephalopathy. Br J Hosp Med (Lond), 2015, 76: 646-654.

3. Wang JY, Zhang NP, Chi BR et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol, 2013, 19: 4984-4491.

4. Bajaj JS, Hafeezullah M, Zadvornova Y et al. The effect of fatigue on driving skills in patients with hepatic encephalopathy. Am. J. Gastroenterol,. 2009, 104: 898-905.

5. Буеверов А.О. Патогенетические основы печеночной энцефалопатии: фокус на аммиак. Клин. перспект. гастроэнтерол. гепатол., 2012, 6: 3-10./Bueverov A.O. Pathogenetic fundamentals of hepatic encephalopathy: focus for ammonia. Klin. Perspekt. Gastroenterol. Hepatol, 2012, 6: 3-10.

6. Плотникова Е.Ю. Роль L-орнитин-L-аспартата в комплексном лечении больных с гипераммониемией. Клин. перспект. гастроэнтерол. гепатол., 2013, 2: 41-49./ Plotnikova E.Y. Role of L-ornitin-L-aspartate in complex therapy of patients with hyperammoniemia. Klin. Perspekt. Gastroenterol. Hepatol, 2013, 2: 41-49.

7. Северин Е.С. Биохимия. ГЭОТАР-Медиа. 2003: 476-489./Severin E.S. Biochemistry. GEOTAR-Media. 2003: 476-489.

8. Butterworth RF., Norenberg MD., Felipo V et al. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int, 2009, 29: 783-788.

9. Amodio P, Montagnese S, Merkel C et al. Attention: minimal hepatic encephalopathy and road accidents. Hepatology, 2012, 55: 985-987.

10. Blanco Vela CI, Poo Ramírez JL. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Ann. Hepatol., 2011, 10(Suppl 2): 55-59.

11. D’Antiga L, Dacchille P, Boniver C et al. Clues for minimal hepatic encephalopathy in children with noncirrhotic portal hypertension. J. Pediatr. Gastroenterol. Nutr., 2014, 59: 689-694.

12. Грюнграйф К., Ламберт-Бауман Й. Эффективность гранул L-орнитин- L-аспартата при лечении хронических заболеваний печени. Сучасна гастроентерология, 2008, 2: 59-66./Grungrife K., Lambert-Bauman J. Effectiveness of L-ornitin-L-aspartate granules for therapy of chronic hepatic disease. Suchasna gastroenterologia, 2008, 2: 59-66.